The Aroon Indicator for GALT entered a downward trend on October 21, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 273 similar instances where the Aroon Indicator formed such a pattern. In 248 of the 273 cases the stock moved lower. This puts the odds of a downward move at 90%.
The Momentum Indicator moved below the 0 level on October 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on GALT as a result. In 83 of 102 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 81%.
GALT moved below its 50-day moving average on October 13, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for GALT crossed bearishly below the 50-day moving average on October 13, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 9 of 11 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 82%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GALT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +8.84% 3-day Advance, the price is estimated to grow further. Considering data from situations where GALT advanced for three days, in 193 of 231 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
GALT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Valuation Rating of 13 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-2.444) is normal, around the industry mean (2.988). P/E Ratio (-7.837) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron PE Growth Rating for this company is 24 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 56 (best 1 - 100 worst), indicating steady price growth. GALT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GALT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The 50-day moving average for ZURA moved below the 200-day moving average on October 02, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
The Momentum Indicator moved below the 0 level on October 21, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ZURA as a result. In 52 of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 63%.
The 10-day moving average for ZURA crossed bearishly below the 50-day moving average on September 16, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 80%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ZURA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
ZURA broke above its upper Bollinger Band on October 14, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ZURA entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ZURA's RSI Oscillator exited the oversold zone, 19 of 23 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The Moving Average Convergence Divergence (MACD) for ZURA just turned positive on October 07, 2026. Looking at past instances where ZURA's MACD turned positive, the stock continued to rise in 41 of 60 cases over the following month. The odds of a continued upward trend are 68%.
Following a +8.40% 3-day Advance, the price is estimated to grow further. Considering data from situations where ZURA advanced for three days, in 152 of 187 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
The Tickeron PE Growth Rating for this company is 20 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 29 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.008) is normal, around the industry mean (2.988). P/E Ratio (-3.688) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating steady price growth. ZURA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ZURA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
GALT | ||
|---|---|---|
OUTLOOK RATING 1..100 | 61 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 13 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 100 | |
PRICE GROWTH RATING 1..100 | 56 | |
P/E GROWTH RATING 1..100 | 24 | |
SEASONALITY SCORE 1..100 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| GALT | ZURA | |
|---|---|---|
| RSI ODDS (%) | N/A | 1 day ago 83% |
| Stochastic ODDS (%) | 1 day ago 87% | 1 day ago 68% |
| Momentum ODDS (%) | 1 day ago 81% | 1 day ago 63% |
| MACD ODDS (%) | N/A | 1 day ago 68% |
| TrendWeek ODDS (%) | 1 day ago 83% | 1 day ago 71% |
| TrendMonth ODDS (%) | 1 day ago 84% | 1 day ago 74% |
| Advances ODDS (%) | 13 days ago 84% | 1 day ago 81% |
| Declines ODDS (%) | 1 day ago 87% | 3 days ago 82% |
| BollingerBands ODDS (%) | 1 day ago 74% | 1 day ago 55% |
| Aroon ODDS (%) | 1 day ago 90% | 1 day ago 77% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
GALT’s FA Score shows that 2 FA rating(s) are green while ZURA’s FA Score has 2 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
GALT’s TA Score shows that 3 TA indicator(s) are bullish while ZURA’s TA Score has 4 bullish TA indicator(s).
GALT (@Biotechnology) experienced а -7.42% price change this week, while ZURA (@Biotechnology) price change was -6.35% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +1.90%. For the same industry, the average monthly price growth was -15.91%, and the average quarterly price growth was -14.30%.
GALT is expected to report earnings on Nov 13, 2026.
ZURA is expected to report earnings on Nov 12, 2026.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| 1 Day | |||
|---|---|---|---|
| CRYPTO / NAME | Price $ | Chg $ | Chg % |
| MINA.X | 0.073968 | 0.002420 | +3.38% |
| Mina cryptocurrency | |||
| CYBER.X | 0.328685 | 0.007381 | +2.30% |
| Cyber cryptocurrency | |||
| GFT.X | 0.000044 | N/A | +0.69% |
| Gifto cryptocurrency | |||
| BAR.X | 0.267393 | -0.000444 | -0.17% |
| FC Barcelona Fan Token cryptocurrency | |||
| WLD.X | 0.582511 | -0.005471 | -0.93% |
| Worldcoin cryptocurrency | |||
A.I.dvisor tells us that GALT and ALT have been poorly correlated (+33% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that GALT and ALT's prices will move in lockstep.
| Ticker / NAME | Correlation To GALT | 1D Price Change % | ||
|---|---|---|---|---|
| GALT | 100% | -1.75% | ||
| ALT - GALT | 33% Poorly correlated | -3.04% | ||
| TAOX - GALT | 32% Poorly correlated | +4.88% | ||
| RNAC - GALT | 32% Poorly correlated | +0.39% | ||
| ZURA - GALT | 30% Poorly correlated | +3.25% | ||
| ACRV - GALT | 29% Poorly correlated | +1.67% | ||
More | ||||
A.I.dvisor indicates that over the last year, ZURA has been loosely correlated with VIR. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if ZURA jumps, then VIR could also see price increases.
| Ticker / NAME | Correlation To ZURA | 1D Price Change % | ||
|---|---|---|---|---|
| ZURA | 100% | +3.25% | ||
| VIR - ZURA | 44% Loosely correlated | -1.58% | ||
| RCUS - ZURA | 42% Loosely correlated | -19.58% | ||
| TNXP - ZURA | 41% Loosely correlated | -6.06% | ||
| FDMT - ZURA | 39% Loosely correlated | -3.66% | ||
| AURA - ZURA | 39% Loosely correlated | -1.52% | ||
More | ||||